Cancer Research Technology and Nuevolution Sign Multi-Target Deal

News   Nov 04, 2013

 
Cancer Research Technology and Nuevolution Sign Multi-Target Deal
 
 
 
 

RELATED ARTICLES

Easily Automate PK Assays for Human IgG Drugs in Preclinical Species

News

At AAPS NBC event, Lumigen produced a poster summarizing the use of their pipetting robot, Andrew which can measure IgG drug concentration in a pre-clinical setting.

READ MORE

Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?

News

A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.

READ MORE

FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia

News

TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE